Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Treatment of multiple sclerosis with the pregnancy hormone estriol.
A much-needed focus on progression in multiple sclerosis.
Extension CombiRx data show no benefit of combined MS drugs
Genzyme provides update on U.S. LEMTRADA™ filing
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Gordon Research Conference on Ion Channels
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Chemotherapeutics in the treatment of multiple sclerosis.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Gordon Research Conference on Myelin Biology and Pathobiology of Myelinating Glia
Antioxidant properties of the triaminopyridine, flupirtine.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...

Pages